Biotech · Private company · Pittsburgh, PA, US
Qrono, Inc
Track this companyFree. Adds Qrono, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- Restoring Tolerance in Inflammatory Bowel Disease with an Oral AMPK agonist Nanomedicine that Targets Antigen Presenting Cells.Fiscal year 2025 · $302.4KNIH RePORTER 5R41DK142311-02 · fetched Nov 12, 2026
- Restoring Tolerance with an Oral AMPK Agonist Nanomedicine Targeting Intestinal Dendritic Cells as a Preventative Therapy for Type 1 DiabetesFiscal year 2024 · $306.5KNIH RePORTER 1R41AI186895-01 · fetched Nov 12, 2026
- Restoring Tolerance in Inflammatory Bowel Disease with an Oral AMPK agonist Nanomedicine that Targets Antigen Presenting Cells.Fiscal year 2024 · $306.5KNIH RePORTER 1R41DK142311-01 · fetched Nov 12, 2026